IP Library › Granted Patent US 12,427,183
Granted Patent B2
US 12,427,183 · App. 17/523,261 · Granted Sep 30, 2025

Methods of treating cancer, infectious disease, and autoimmune disease using chemokines

Inventor: Franck Barrat (New York, NY)
Assignee: New York Society For The Relief Of The Ruptured And Crippled, The Hospital For Maintaining, Special Surgery
A61K38/195A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,183
App. No.
17/523,261
Granted
Sep 30, 2025
Kind
B2
Abstract

The current invention is related to the prevention and treatment of diseases including cancer, autoimmune disease, and infectious disease using chemokines and the receptors to which they agonize. It has been found that certain chemokines, including CXCL4, CXCL9, CXCL10, and CXCL12 as well as CCL5 have various effects on toll-like receptors in various cell types and these can be utilized for disease treatment and prevention.

Claims (14)

1. A method of activating an immune response in a subject having cancer, comprising administering to the subject a therapeutically effective amount of a chemokine selected from the group consisting of CXCL10, CXCL12 and CCL5, wherein the chemokine potentiates the response of toll-like receptor (TLR) 9 to produce interferon-α in plasmacytoid dendritic cells from the subject and the activation of the immune response is beneficial to treating cancer.

2. The method of claim 1 , wherein the cancer is chosen from the group consisting of lung cancer, colon cancer, melanoma, pancreatic cancer, mammary cancer, prostate cancer, breast cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, cervical cancer, colon and rectum cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, cancer of the head and neck, kidney cancer, larynx cancer, liver cancer, fibroma, neuroblastoma, oral cavity cancer, skin cancer, testicular cancer, thyroid cancer, uterine cancer, medulloblastoma, sarcoma, squamous cell carcinoma, and lymphoma.

3. The method of claim 1 , wherein the chemokine is administered by injection directly into a tumor in the subject.

4. The method of claim 1 , further comprising administering to the subject an agonist of TLR9.

5. The method of claim 4 , wherein the agonist is chosen from the group consisting of CpG nucleotides, CpG-A, CpG-B and CpG-C.

6. The method of claim 4 , further comprising administering to the subject a checkpoint inhibitor.

7. The method of claim 6 , wherein the checkpoint inhibitor inhibits a protein selected from the group consisting of CTLA-4, PD-L1, PD-L2, and PD-1.

8. The method of claim 1 , wherein the chemokine is administered via the administration of plasmacytoid dendritic cells into tumor tissue in the subject, wherein the plasmacytoid dendritic cells have been contacted ex vivo with the chemokine peptide or protein and further contacted with an agonist of TLR9.

9. The method of claim 8 , wherein the plasmacytoid dendritic cells were obtained from the subject.

10. The method of claim 8 , wherein the TLR9 agonist is chosen from the group consisting of CpG nucleotides, CpG-A, CpG-B and CpG-C.

11. A method of increasing the effectiveness of an immunogenic composition comprising at least one CpG in protecting against an infectious disease in a subject comprising administering a therapeutically effective amount of a chemokine selected from the group consisting of CXCL10, CXCL12 and CCL5, wherein a therapeutically effective amount of the immunogenic composition comprising at least one CpG has been administered or will be administered to the subject and wherein the chemokine potentiates the response of toll-like receptor (TLR) 9 to produce interferon-α in plasmacytoid dendritic cells from the subject and the activation of the immune response increases the effectiveness of the immunogenic composition.

12. The method of claim 11 , wherein the infectious disease is chosen from the groups consisting of chickenpox, diphtheria, hepatitis A, hepatitis B, human papillomavirus, influenza, measles, tetanus toxoid, anthrax, leishmania, shingles, mumps, rubella, polio, rotavirus, whooping cough, meningitis and COVID 19 (SARS-CoV-2 virus).

13. A method of protecting a subject having cancer from an infectious disease comprising administering to the subject a therapeutically effective amount of a chemokine selected from the group consisting of CXCL10, CXCL12 and CCL5 and a therapeutically effective amount of an immunogenic composition comprising at least one CpG, wherein the chemokine potentiates the response of toll-like receptor (TLR) 9 to produce interferon-α in plasmacytoid dendritic cells from the subject and the activation of the immune response is beneficial to treating cancer.

14. The method of claim 13 , wherein the infectious disease is chosen from the group consisting of chickenpox, diphtheria, hepatitis A, hepatitis B, human papillomavirus, influenza, measles, tetanus toxoid, anthrax, leishmania, shingles, mumps, rubella, polio, rotavirus, whooping cough, meningitis and COVID 19 (SARS-CoV-2 virus).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2021
From: BARRAT, FRANCK
To: NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY
Reel/Frame 058191/0980 →
Continuity (4)
Continuation In Part 15839105 · Dec 12, 2017
Provisional Application 62492562 · May 1, 2017
Provisional Application 62433038 · Dec 12, 2016
Related Publication 20220072100A1 · Mar 10, 2022
References Cited (33)
US 11197890B2 · Barrat · 2021 [cited by examiner]
Swiecki, et al. The multifaceted biology of plasmacytoid dendritic cells. Nature Reviews Immunology. Aug. 2015. 15(8):471-85. (Year: 2015). [cited by examiner]
Romagnani, et al. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on Th1 or Th2 cytokine production. Journal of Allergy and Clinical Immunology. Dec. 2005. v116(6):1372-79. (Year: 2005). [cited by examiner]
Gupta, et al. CpG oligodeoxynucleotides as TLR9 agonists. Biodrugs. 2010. 24(4):225-35. (Year: 2010). [cited by examiner]
Wang et al (PNAS E7240-7249, published online Oct. 31, 2016) (Year: 2016). [cited by applicant]
Batteux et al., New insights on chemically induced animal models of systemic sclerosis. [cited by applicant]
Blanco et al., Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. [cited by applicant]
Cederblad et al., Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha-producing cells. [cited by applicant]
Van Bon et al., Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. [cited by applicant]
Guiducci et al., TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. [cited by applicant]
Huang et al., Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. [cited by applicant]
Koca et al., Effectiveness of etanercept in bleomycin-induced experimental scleroderma. [cited by applicant]
LeRoy and Medsger, Jr., Criteria for the classification of early systemic sclerosis. [cited by applicant]
Tan et al., Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. [cited by applicant]
Barrat et al., Nucleic Acids of Mammalian Origin Can Act as Endogenous Ligands for Toll-like Receptors and May Promote Systemic Lupus Erythematosus. [cited by applicant]
Chia et al., Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. [cited by applicant]
Demaria et al., TLR8 deficiency leads to autoimmunity in mice. [cited by applicant]
Duramad et al., IL-10 regulates plasmacytoid dendritic cell response to CpG-containing immunostimulatory sequences. [cited by applicant]
Guiducci et al., Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9. [cited by applicant]
Guiducci et al., RNA recognition by human TLR8 can lead to autoimmune inflammation. [cited by applicant]
Guiducci et al., PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. [cited by applicant]
Guiducci et al., Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. [cited by applicant]
Hochberg, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. [cited by applicant]
Lafyatis et al., B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. [cited by applicant]
Mayes et al., Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. [cited by applicant]
Rice et al., A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. [cited by applicant]
Rowland et al., Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. [cited by applicant]
Sisirak et al., Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. [cited by applicant]
Van den Hoogen et al., 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. [cited by applicant]
Varga and Abraham, Systemic sclerosis: a prototypic multisystem fibrotic disorder. [cited by applicant]
Wenzel and Tuting, An IFN-Associated Cytotoxic Cellular Immune Response against Viral, Self-, or Tumor Antigens Is a Common Pathogenetic Feature in “Interface Dermatitis”. [cited by applicant]
Yamamoto et al., Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. [cited by applicant]
Yamamoto and Nishioka, Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. [cited by applicant]